Kemik İliği Transplantasyonu Ve Hematolojik Hastalıklarındaki Yeri

Year 1987, Volume: 40 Issue: 2, 151 - 168, 30.06.1987

Dilek Dinçol

https://izlik.org/JA63ZC38EB

Abstract

Kemik iliği transplantasyonunda (KİT) amaç, hastanın anormal hematopoetilç sistem hücrelerinin yerini vericinin normal hematopoetik sistem hücrelerinin almasını sağlamaktadır. Alıcı ile vericinin genetik ilişkisine göre üç tip KİT olabilir : Singeneik, allogeneik ve otoog KİT. Allogeneik KİT'nun en önemli komplkiasyonları greftin reddi, akut ve kronik graft-versus-host hastalığı, enfeksiyonlar ve hasta lığın nüksüdür, Otolog kemik iliği transplantasyonunda ise en önemli problem hastalığın nüksetmesidir, Akut lösemiler, kronik myelositer lösemi, aplastik anemi, talasemi majör gibi hematolojik hastalık immün yetmezliklerde ve kemoterapiye duyarlı solid tümörlerde yüksek doz ilaç uygulayabilmek için KİT yapılmaktadır.
Hiç transfüzyon yapılmamış aplastik anemilerde KİT ile % 80 oramnda başarılı sonuç alınmaktadır, Akut lenfoblastjk lösemide 2. re.. misyon döneminde KİT önerilmekte ve % 25 - 50 oranında uzun süreli yaşam elde edilmektedir, Akut myeloblastik löseminin ilk remisyon döneminde ve 30 yaşından daha genç hastalarda yapılan KİT ile % 40 - 65 uzun süreli survive sağlanabilmektedir. Kronik myelositer löseminin kronik fazında KİT ile elde edilen sonuçlar da umut vericidir

Keywords

kemik iliği , hematolojik , transplantasyon

Project Number

-

Bone Marrow Transplantation and Its Role in Hematological Diseases

https://izlik.org/JA63ZC38EB

Abstract

The aim of bone marrow transplantation (BMT) is tö replace the abnormaıl hematopoetic celis of the patient *ith the normal hematopoetic celis of donor. BMT is 3 types according to the genetic relationship between the donor and recipients : syngeneic, allogeneic and au-
tolog. The most important complications of allogeneic BMT are graft failüre, acute graft-versus-host disease, infections and recurrence of disease. Recurrence of disease is the most significant problem in autolog BMT, also. BMT is being applied in hematologic diseases hike that acute leukemia, chronic myeloid leukemia, aplastic anemia, thalassemia majör, in immüne deficiencies and inborn errors of metabolism, and in the solid tumors which are higly responsible to chemotherapy.
BMT is succesfull in 80 percent of the patients with aplastic anemia who were not transfused before transplantation. BMT is recommended in the second remission of ALL with disease free long-term survival in 25 to 50 per cent of patients, BMT is applied in the first remission of AML. Long-term survival can be achieved in 40-60 percent of patients who are younger than 30 years old. The results of BMT in chronic phase of chronic myeloid leukemia are encouraging,

Keywords

bone marrow , transport , hematology

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Appelbaum FR, Dahlberg S, Thomas ED : Bone marrow transplatltalion or chemotherapy after remission induction for adults with acute non-lymphoblastic leukemia. Ann Intern Med 101 : 591, 1984.
• 2. narrett AJ, Kendra JR, Lucas CF : Bone marrow transplantation for acute lympnoblastic leukemia. Br J HEtemttt 52 . 181, 1982.
• 3. Berk ÖA, Üskent N, YalGJn A : AtL'li bir olguda HLA ve MLR lasmi uygunluk gösteren yalan alcrabadan allogeneik kemik i)ìúi transplantasyonu. Dog•a 10 (3) : 237. 1986.
• 4 Blume KG, Beutler E, Bross K, et al : Bone marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 302 : 41, 1980.
• 5. S. Champlin R, Ho W, Arenson E, ec al : Allogencic bone marrow transplantation for chronic myelogenous leukemipv in chronic or accolareted phase. Blood 60 1038, 1982.
• 6. Dicke KA. Spitzer G ; Clinical studies of autografting in acute lymphocytic leukemia. In Clinics in Haematology, Goldstone AH (ed). Vol. No. 1 p. 85-103. Feb. 1986. 7. Doney KC, Weiden PL Storb R, et al : Failure of early administration ot antithymosit globülin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients, Transplantation 31 : 141, 1981.
• 8, Fofer A, Chever MA, Greenberg PD, et al ; Treatment of chronic granulocytic leukemia With chemoraðiotherapy and transplantation of marrow from idon tical twins. N Engl J Med 306 63. 1982.
• 9. Filipovich AH : Allogeneic bone marrow transplantation on with related donors other than HLA MLC-Matched siblings. Transplantation 3B 282. 1085.
• 10. Forman SJ, Spruce WE, Farbstein MJ, et al : Bone marrow ablation folloved by allogeneic marrow grafting during first complete remission of acute non: lyniphcblastic leukemia. Blood 01 : 439, 1083.
• 11Gale PUP, Kersey JA-I, noctiitx MM, el al •s Bone-marrow transplantation for acute lymphoblastic leukemia, Lancet 2 : 663, 1983.
• 12. 1B. Gotti RA, Meuwissen HJ, Allen HD. et al : Immunologic reconctruction of sex linked lymphopenic immunological deficiency. Lancet 2 1336, 1968.
• 13. Gluclcman E, Barrett AS, Arcese W, et al ; Bone marrow transplantation in severe aplastic anemia : A survey of the European group for bone marrow transpAa.ntaiuion. Br J Haematol 49 165* 1981.
• 14. Gorin NC, Herve P. Aegerter P, et al : Autologous bone marrow transplanta tion for acute leukemia in remission Br J Haematol 64 : 385, 1986.
• 15. Grob JP, Grundy JE, Prentice HG, et al ; Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet. 1 774, 1987.
• 16. Johnson FL, Thomas ED, Clark BS, et al A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remisison. N ungl J Med 305 ; 846, 1981.
• 17. Kamani N, August CS : none marrow : Problems and pros pects. In The Medical Clinics of North America Vol. 68, No. 3. May 1084.
• 18. Klingemann HG, Storb R, Fefer A, et al Bone marrow transplantation in patients aged 45 years or older, Blood 67 770 ,19Ûð. 19. Linch DC, Burnett AK Clinical studies ot autolozous bone marrow transplan-tations in acute myeloid leukemia. In Clinics in Haemat010gy-Autologous Bo no Marrow Transplantation-Goldstone AH (ed). Vol. 15, No. p. 1030B, Veb 1986.